Insightful Discussions on eMobility Await: Join Influential Speakers at London EV Show 2024 ACN Newswire

Insightful Discussions on eMobility Await: Join Influential Speakers at London EV Show 2024

LONDON, Oct 2, 2024 - (ACN Newswire via SeaPRwire.com) - The London EV Show 2024 has secured an impressive lineup of top experts from across the mobility value chain. This includes influential policymakers, industry associations, EV manufacturers, innovators in charging infrastructure, battery management specialists, and fleet management professionals, providing a vital opportunity for meaningful engagement for anyone seeking to navigate the future of electric transportation.The event's agenda is rich with insights into the latest advancements and breakthroughs within the electric vehicle sector. Key topics of discussion will include, the United Kingdom's EV outlook and transition to net-zero, electrifying mobility and transportation as a journey towards a sustainable future, and navigating the global EV landscape through policies, regulations, and outlook. Additionally, discussions will cover urban mobility and smart cities, powering the future with electrification across air, sea, and land transportation, and the cleantech and decarbonisation of the global transport sector.Other important topics pertain to empowering women in the electric vehicle industry, cybersecurity in EVs, consumer behaviour, and market trends, as well as investing in the global EV revolution. The agenda also addresses battery management systems and charging infrastructure, EV charging systems and payment solutions, and the relationship between charging, battery technology, and the supply chain.Notable speakers who have confirmed their participation at #LEVS24 include: Alex Gilbert, Head of Energy and Electrification, Commercial Development at Transport for London; Stuart Murphy, Head of Fleet Transformation and Integration at Royal Mail; Mete Coban, Deputy Mayor of London for Environment and Energy at Greater London Authority; James Rooney, Head of Road Fleet at Network Rail; Stephen Elderkin, Director of Environmental Sustainability at National Highways; Olly Craughan, Head of Sustainability at DPD UK; Alex Veitch, Director of Policy and Insights at British Chambers of Commerce; Dr. Roger Tyers, Transport Policy Specialist at the House of Commons Library; Sofia Stayte, Head of Future of Flight Policy at the Department for Transport UK; H.E. Rafael Ortiz Fabrega, Ambassador of Costa Rica in the United Kingdom and Northern Ireland at the Embassy of Costa Rica; Oliver Adrian, Head of EV Charging & Energy Strategy at Ford Motor Company; Marc Palmer, Brand Insight Director at Auto Trader UK; Marina Lussich, Principal, Operations Sustainability at Amazon; Dr. David Storer, Director of Research, Innovation and New Mobility at CLEPA - European Association of Automotive Suppliers; Amy Stokes, Head of e-mobility at Volvo; Matthew Eastwood, Head of EV Infrastructure, Consumer Incentives and Fleets at Transport Scotland; Andrew Grant, Head of Intelligent Mobility at Bloomberg NEF; Abby Chicken, Head of Sustainability at Openreach; Baerte De Brey, Vice President at AVERE. Check The Whole List HereThe London EV Show 2024 is a one-stop destination for anyone passionate about electric mobility. It offers a chance to connect with industry leaders and innovators, engage in dynamic discussions, and explore the latest trends and technologies shaping the future of transportation.Don’t miss this opportunity to make a meaningful impact! For further information, please reach out to us at press@valiantandcompany.com Copyright 2024 ACN Newswire via SeaPRwire.com.
More

从鞋子到酒精,这些产品将受到码头工人罢工的影响

(SeaPRwire) -本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。随着美国码头工人从缅因州到德克萨斯州的主要港口罢工,这些产品可能会受到影响。
More

NEFECON Included in 2024 KDIGO Clinical Practice Guidelines

HONG KONG, Oct 2, 2024 - (ACN Newswire via SeaPRwire.com) - Recently, Everest Medicines has announced another positive development. The company’s lead product, NEFECON, as the only in-disease IgA nephropathy (IgAN) treatment, has been included in the “KDIGO 2024 Clinical Practice Guideline for the Management Of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV) (Public Review Draft)” (hereinafter referred to as the “New Guidelines (Draft)”), recommending treatment with a 9-month course of NEFECON for patients who are at risk of progressive kidney function loss with IgAN (2B). This significant milestone further solidifies Everest Medicines' leadership in the treatment of IgAN and brings new hope to IgAN patients worldwide.NEFECON Ushering in a New Era of Standardized Treatment of IgA NephropathyAccording to the New Guidelines, NEFECON is the only treatment to date proven to reduce levels of pathogenic forms of IgA and IgA immune complexes. The inclusion of NEFECON in the New Guidelines Draft solidifies NEFECON as the first-line cornerstone in the treatment of IgAN, ushering in a new era of standardized treatment. With the imminent release of China’s first-ever IgAN guidelines, NEFECON is expected to be recommended as the first-line treatment for IgAN patients at risk of disease progression, further reinforcing its pivotal role in clinical practice.According to Everest Medicines’ recent financial reports, NEFECON has generated RMB 167.3 million in sales revenue just over a month after its commercial launch and first prescription in mainland China in May 2024, demonstrating strong market demand. NEFECON has been commercially launched in mainland China, Macau, and Singapore, and has also been approved in Hong Kong. The New Drug Application (NDA) of NEFECON has been accepted in South Korea, signaling steady progress in global commercialization.In the second half of 2024, Everest Medicines will continue to promote the sales of NEFECON in mainland China and other regions in the Asia-Pacific, while actively participating in China’s National Reimbursement Drug List (NRDL) negotiations to further enhance the affordability and accessibility. It is expected that 2025 will be a breakout year for NEFECON sales, with promising potential for the future.Core Products Performing Strongly, Differentiated Pipeline Further RefinedAccording to Everest Medicines’ interim results for the first half of 2024, the company’s total revenue reached RMB 301.5 million, marking a significant growth of 158% compared to the second half of 2023, and achieved commercial level profitability. The commercial launch of NEFECON has been a key driver behind this revenue growth. In addition, XERAVA (eravacycline), the world’s first-in-class fluorocycline antibiotic, also performed exceptionally well, generating RMB 134.2 million in sales in the first half of 2024. As the availability of XERAVA expands to reach more patients, its revenue is expected to grow further.Within the autoimmune disease portfolio, the lead product VELSIPITY (etrasimod) has been approved in Macau and Singapore, with plans to submit a New Drug Application (NDA) in mainland China and Hong Kong in the second half of 2024, alongside a commercial launch in Macau. Everest Medicines is expected to have three commercialized products by the end of 2024, further refining its differentiated pipeline development and driving the company into a new phase of growth.In terms of innovative R&D, Everest Medicines owns a proprietary mRNA development platform with full intellectual property and global rights, focusing on developing both preventive and therapeutic self-developed mRNA products. In August 2024, Everest announced the launch of the first-in-human Investigator-Initiated Clinical Trial (IIT) for EVM16, a personalized mRNA cancer vaccine program. Everest Medicines is anticipated to submit investigational new drug applications in the United States and China in 2025 for EVM14, a Tumor-Associated Antigens (TAA) cancer vaccine program.In addition, EVER001, a next-generation covalent reversible BTK inhibitor, with global rights, is under development for the treatment of renal diseases worldwide. The company is expected to announce the topline results of its Phase 1b study in membranous nephropathy in the second half of 2024.With the company’s dual-engine strategy of in-house discovery and global in-licensing, Everest Medicines continues to expand its product pipeline and drive business growth. The company maintains its revenue guidance of RMB 700 million for 2024 and remains confident in achieving cash flow break-even by the end of 2025.With NEFECON being included in multiple authoritative domestic and international treatment guidelines, along with the ongoing R&D and promotion of numerous core products. Everest Medicines has once again demonstrated its leading position in the global biopharmaceutical field. Armed with its robust pipeline and continuous innovative R&D capabilities, the company is steadily advancing towards becoming a top-tier player in the global pharmaceutical industry. Copyright 2024 ACN Newswire via SeaPRwire.com.
More
Eisai Commences Business Activities At New Pharma Sales Subsidiary In Saudi Arabia JCN Newswire

Eisai Commences Business Activities At New Pharma Sales Subsidiary In Saudi Arabia

Eisai Co., Ltd. announced today that fully-fledged operations and business activities have begun at Eisai Pharmaceuticals Single Person Limited Liability Company (Eisai Saudi Arabia), a pharmaceutical sales subsidiary recently established in Riyadh in the Kingdom of Saudi Arabia (Saudi Arabia). Eisai Saudi Arabia is a wholly-owned subsidiary of Eisai’s European regional headquarters, Eisai Europe Ltd. (Location: U.K.).In the 1960s, Eisai started business in the Middle East marketing and selling Eisai products throughlocal distribution partners. In Saudi Arabia, Eisai began selling the peripheral neuropathy treatmentMethycobal® in 2009, and has since expanded the product pipeline with the launch of antiepileptic drug Fycompa® in 2018, anticancer drug Lenvima® in 2020, and others, through local distribution partners.Eisai Saudi Arabia was established in April 2024 in order to build an in-house sales system in Saudi Arabia, and is in the process of taking over commercial rights for the Eisai products in Saudi Arabia from local distribution partners. Eisai Saudi Arabia started sales and marketing activities for Methycobaland Fycompa in October 2024, and plans to expand activities to include Lenvima and anticancer agent Halaven® from April 2025. Moreover, an application for Alzheimer’s disease treatment lecanemab(generic name, global brand name: Leqembi®) has been submitted for review in Saudi Arabia.Saudi Arabia’s pharmaceutical market reached 11,342 million USD in 2023, making it the largest market in the Middle East, with an average growth rate of 7% in local currency terms from 2019 to 2023.1With the commencement of operations at Eisai Saudi Arabia, Eisai aims to utilize its own drug salessystem in Saudi Arabia, deliver innovative new drugs to more patients in the country as quickly aspossible, and contribute to improving the benefits of patients and their families.1. Outline of Eisai Saudi Arabia1) Company Name: Eisai Pharmaceuticals Single Person Limited Liability Company2) Location: Riyadh, Kingdom of Saudi Arabia3) Scope of Business: Import and marketing of pharmaceutical products4) Charter Capital: 32,800,000 Saudi Riyal (approximately 1.25 billion JPY)5) Shareholder: Eisai Europe Ltd.6) Date of Establishment: April 2, 2024About the Pharmaceutical Market in Saudi ArabiaSaudi Arabia has a population of about 35 million and a GDP per capita of 118,216 Saudi riyals (approx. 31,445 USD). Saudi Arabia also has the largest pharmaceutical market in the Middle East, reaching 11,342 million USD in 2023 with an average growth rate of 7% in local currency terms from 2019 to 2023.(1)The healthcare market in Saudi Arabia consists of two major segments, the public sector and private sector.The public sector is fully funded by the government, and provides all public sector employees and their families, as well as Saudi Arabia citizens without health insurance, with access to medical care for free at government facilities.2 In the private sector, companies are required to offer health insurance for their employeesand expenses are dependent on the insurance policy.(2)In 2016, Saudi Arabia announced Vision 2030, an economic reform concept toward 2030 with the aim to shift Saudi Arabia to an economy that doesn’t rely on oil. In response to Vision 2030, the Ministry of Health of Saudi Arabia aims to build a more effective and comprehensive medical system, expanding health services and medical facilities and digitalization.(1) Created based on IQVIA World Review Analyst 2024, Data Period 2019-2023 (Copyright ©2024 IQVIA.). Reprinted with permission.(2) Ministry of Economy, Trade and Industry, Medical and International Expansion Country Report: Saudi Arabia https://tinyurl.com/rwn8883c Media Inquiries:Public Relations DepartmentEisai Co., Ltd.+81-(0)3-3817-5120 Copyright 2024 JCN Newswire via SeaPRwire.com.
More
花房集团复牌命悬一线 ACN Newswire

花房集团复牌命悬一线

香港, 2024年10月2日 - (亚太商讯 via SeaPRwire.com) - 拥有直播平台花椒和六间房的花房集团(03611)即将触发香港证券交易退市政策红线,若公司连续停牌18个月,将被视为自愿退市。花房集团自2023年4月因被投资公司调查而停牌以来,已达17个月。停牌期间花房集团的业务并未受影响,2024年半年报显示,集团期内总收益为9.65亿元(人民币,下同),股东应占溢利3448.9万元,同比大增105%。其中海外社交网络收益更是同比增长9.8%至1.39亿元。目前花房集团已向港交所提交复牌文件,若通过港交所审核,花房集团将成为今年第一个实现自救,成功复牌的停牌上市公司。2022年12月12日花房集团正式登陆香港联合交易所。(资料图片)根据港交所最新数据显示,截至7月31日,2024年除牌公司25家,已获上市委员会批准的除牌公司6家,还有高达79家上市公司处于长期停牌状态。仔细分析被除牌的25家上市公司,有几个特征:一是市值较小,二是大部分属于消费行业,且无实质性经营业务,没有足够的业绩支撑其上市地位,有「养壳」之嫌。与很多停牌上市公司业务「摆烂」不同,花房集团在众多停牌公司中显然是个异类。8月26日花房集团公布2024年中期业绩报告显示,报告期内,花房集团国内直播及音频社交网络业务收益达8.13亿元。虽然受停牌影响业务有所下滑,但花椒和六间房在直播平台市场的占有率一直靠前。记者打开花椒直播和六间房网,均能正常观看直播。在六间房网的「关于我们」介绍里表示,六间房是首批文化部授权的「网络演出试点单位」之一,总注册用户已达6000万,网站拥有签约艺人25万,日演艺总时长超过5万小时。与此同时,花房集团海外社交业务展现出强劲的增长势头。中报显示,花房集团海外社交网络收益同比增长9.8%至1.39亿元,其中海外社交业务的HOLLA Group上半年收益达1.5亿元,规模暂不及内地直播业务,但其除税前可呈报部分利润达4231.3万元,相较于集团业务总和的7109.7万元,占比高达59.5%。花房集团认为,这一增长主要得益于集团海外业务对其核心市场如北美市场的精准定位,以及旗下HOLLA、MONKEY等产品在全球范围内的用户规模扩张。记者进入Google市场看到,旗下专注于北美市场的视频社交软件MONKEY下载量已达1000万以上,颇受美国年轻人喜欢。值得留意的是,截至2024年6月30日,花房集团的现金及现金等价物约为人民币19.3亿元,现金流可谓充裕。今年5月花房集团收到港交所复牌指引,7月2日,花房集团再次发布公告表示,将向联交所递交经更新复牌建议书,以证明本公司已达成复牌指引所载有关恢复本公司股份买卖的条件。花房集团可谓含着「金汤匙」出生,互联网「红衣教主」周鸿祎作为花房集团的实际控制人通过奇虎360、花椒壹号及花椒贰号控制花房集团约36.46%的股权。花房集团的第二大股东是宋城演艺,通过其全资附属公司Global Bacchus Limited持股花房集团约35.35%的股权。受经济大环境影响,花房集团两大股东的日子并不好过,周鸿祎担任董事长三六零安全科技股份有限公司刚发布的2024年中报显示,上半年凈现金流为-67.45亿元,同比下滑518.03%。受花房集团停牌影响,宋城演艺甚至已经在2023年财报中计提了巨额的长期股权投资减值准备,导致公司凈利润出现亏损。2024年中报显示,宋城演艺凈现金流为2.66亿元。两大股东的现金流都不如花房集团19.3亿元充裕。表面上看,如果花房集团退市,那么周鸿祎和宋城演艺两大股东将蒙受极大损失。可是在花房集团拥有19.3亿元现金的情况下,如果退市,两大股东或成最大赢家。一旦启动退市流程,不论是私有化还是彻底退市,周鸿祎和宋城演艺两大股东都将掌握着19.3亿元现金的分配权,花房集团现金被分配后,料将极大缓解两大股东的现金流问题,特别是对周鸿祎而言,一旦获得花房集团的现金流,将极大地改善其财务状况。对于中小投资者而言,最不愿看到的结果是花房集团退市,被锁定了18个月流动性的资金或将一无所获,由于退市涉及清盘等复杂程序,想要拿回投资款同样要经过复杂的法律程序,对于何时能够拿回投资款以及能否拿回投资款都存在极大的不确定性。如今,花房集团已经站在了能否复盘的十字路口,如果在港交所最后期限花房集团递交文件无法通过审核,花房集团将不得不面临私有化或者退市风险,那么对中小股东而言都是最坏的结果。目前,花房集团还在等待港交所最后的审核结果,对于有真实业务有现金流积极争取复盘的停牌上市公司,交易所在复牌审核上也应该有新的标准,不该像对待「殭尸」上市公司那样「一刀切」,让其一退了之。 Copyright 2024 亚太商讯 via SeaPRwire.com.
More

云顶新耀耐赋康入选《2024版KDIGO指南草案》 中期业绩强劲增长 展现行业领军地位

香港, 2024年10月2日 - (亚太商讯 via SeaPRwire.com) - 近日,云顶新耀再度传来利好消息,其核心产品耐赋康(布地奈德肠溶胶囊,NEFECON)作为唯一的对因治疗药物,被纳入《2024版KDIGO IgA肾病和IgA血管炎临床管理实践指南(公开审查草案)》(以下简称"新版指南(草案)"),推荐有疾病进展风险的IgA肾病患者进行9个月的耐赋康治疗(2B)。这一重大进展不仅进一步巩固了云顶新耀在IgA肾病治疗领域的领导地位,也为全球IgA肾病患者带来了新的治疗希望。耐赋康作为治疗IgA肾病的"新标准"作为目前唯一被证实能够降低IgA和IgA免疫复合物水平的治疗方法,耐赋康在IgA肾病治疗中展现了独特的优势。此次纳入新版指南草案,确立了耐赋康在IgA肾病中的一线基石地位,标志着该领域规范化治疗进入了全新时代。随着中国首部IgA肾病指南的即将发布,耐赋康也有望被纳入作为有疾病进展风险的IgA肾病患者的一线治疗药物,将进一步提升其在临床实践中的核心地位。根据财报数据显示,自耐赋康2024年5月在中国内地首次开出处方以来,上市后仅一个多月产品销售收入高达1.673亿元,显示出市场对该产品的巨大需求。截至目前,耐赋康已在中国内地、中国澳门和新加坡成功商业化上市,幷于中国香港获批。此外,耐赋康的新药上市许可申请已在韩国获得受理,全球商业化布局正在稳步推进。2024年下半年,云顶新耀将继续推动耐赋康在中国大陆和亚太其他地区的销售,幷积极参与中国国家医保谈判,进一步提升药品的可及性和负担能力。预计2025年将成为耐赋康的销售爆发期,未来潜力可期。核心产品表现强劲 差异化管线布局日益完善根据云顶新耀2024年中期财报,公司上半年收入大幅增长至人民币3.02亿元,较去年下半年增长158%,幷实现公司历史上的首次商业化盈利。耐赋康的成功商业化是推动公司收入增长的主要动力。此外,全球首个氟环素类抗菌药物依嘉(XERAVA)在2024年上半年也表现亮眼,销售收入达到人民币1.342亿元。随着依嘉的持续推广,其市场表现将进一步提升。在自身免疫疾病领域,重磅药物伊曲莫德(VELSIPITY)已在中国澳门和新加坡获批,预计于2024年下半年在中国内地及中国香港递交新药上市申请,幷计划同步在中国澳门实现商业化。预计到2024年底,云顶新耀将有三款产品实现商业化上市,进一步完善差异化管线发展格局,推动公司迈向新的增长阶段。在创新研发方面,云顶新耀拥有一个具有全部知识产权及全球权益的mRNA平台,用来开发预防及治疗性的mRNA自研产品。2024年,云顶新耀将专注于开发具有自主知识产权的突破性肿瘤治疗性疫苗项目。目前,首个自主研发的新型mRNA个性化肿瘤治疗性疫苗EVM16已于今年8月正式启动临床试验,计划将在2025年于中美两地递交肿瘤相关抗原(TAA)疫苗的新药临床试验申请。此外,拥有全球权益的重磅药物EVER001,作为新一代高效的共价可逆BTK抑制剂,正在全球范围内进行肾病治疗的开发。2024年下半年,公司预计将公布其针对膜性肾病的1b期临床研究顶线结果。云顶新耀通过自主研发和全球授权引进的"双轮驱动模式",持续扩大产品管线,推动业务增长。公司预计于2024年实现全年人民币7亿元的销售目标,幷力争在2025年底前实现现金盈亏平衡。随着耐赋康被纳入多项国内外权威治疗指南,以及众多核心产品的持续研发及推广,云顶新耀再次证明了其在全球生物制药领域的领军地位。凭借其丰富的产品管线和不断创新的研发能力,云顶新耀正在稳步迈向全球生物制药行业的顶尖梯队。 Copyright 2024 亚太商讯 via SeaPRwire.com.
More
Graid Technology Inc. and KLC Group Forge Groundbreaking Partnership to Redefine High-Speed RAID and Data-at-Rest Security ACN Newswire

Graid Technology Inc. and KLC Group Forge Groundbreaking Partnership to Redefine High-Speed RAID and Data-at-Rest Security

SANTA CLARA, CA, Oct 1, 2024 - (ACN Newswire via SeaPRwire.com) - As data demands surge in today's hyper-competitive landscape, organizations are constantly seeking solutions that balance cutting-edge security with uncompromised performance. A new strategic partnership between Graid Technology, creators of SupremeRAID™, and KLC Group, innovators behind CipherDriveOne Plus, is set to redefine this balance with a first-of-its-kind solution for high-speed storage and NSA CSfC-certified Data-at-Rest (DAR) Security.Graid Technology Inc. and KLC Group Secure Groundbreaking Partnership to Disrupt High-Speed RAID and Data-at-Rest SecurityAt the core of this collaboration is a novel approach to data security. Combining the National Security Agency's (NSA) Commercial Solutions for Classified (CSfC) Data-at-Rest (DAR) Security guidelines, the joint solution integrates encryption, access controls, and authentication to deliver military-grade data protection. This breakthrough is designed to meet the critical needs of government contractors and organizations that require NSA CSfC-certified protection alongside high-performance RAID storage.While CipherDriveOne Plus provides robust hardware-based full-disk encryption, traditional RAID solutions have presented challenges, including drive-locking mechanisms that limit the performance of CSfC-compliant NVMe SSDs or spinning disks. SupremeRAID™ by Graid Technology offers a groundbreaking alternative. As a GPU-accelerated software RAID, SupremeRAID™ eliminates the bottlenecks and limitations of hardware RAID, allowing CSfC-compliant systems like CipherDriveOne Plus to operate without compromising authentication processes or drive performance. This results in superior data protection and seamless NVMe SSD operation.CipherDriveOne Plus, a Hardware Full Disk Encryption - Authorization Acquisition (AA) solution, is designed to meet the U.S. Government's strict Data-at-Rest (DAR) standards. It provides key management, encryption, and authentication over OPAL 2.0 self-encrypting SSDs or HDDs, ensuring immediate data protection that is OS-agnostic and governed by FIPS-140-2 level key encryption with options for single, two-factor, or multi-factor authentication."We are thrilled to embark on this new journey with our esteemed partner, where innovation meets collaboration. Together, we have achieved remarkable milestones and won several government customers in a short time. There is no other solution capable of our joint technology in the market today," said Kurt Lennartsson, CEO of KLC Group."By joining forces with KLC Group, we are redefining the performance and security benchmarks in high-performance computing, AI, and diverse industries reliant on data-intensive operations," stated Leander Yu, President and CEO of Graid Technology. "The collaboration between SupremeRAID™ and CipherDriveOne Plus not only enhances performance but also ensures comprehensive data protection, scalability, and flexibility."To explore the advanced data protection and storage performance offered by this partnership, download the solution brief.For more information:Graid Technology: https://www.graidtech.com/federal-and-public-sector/KLC Group: https://klc-group.com/CipherDriveOne: https://www.cipherdriveone.comAbout KLC Group and CipherDriveOneKLC Group is a leading provider of cybersecurity solutions, dedicated to safeguarding organizations from evolving cyber threats. With a focus on innovation and excellence, KLC Group has consistently delivered cutting-edge security solutions tailored to meet the unique needs of its clients. Learn more: www.klc-group.comAbout Graid Technology and SupremeRAID™Graid Technology is led by a dedicated team of experts with decades of experience in the SDS, ASIC, and storage industries, and continues to push boundaries in data storage innovation by protecting NVMe-based data from the desktop to the cloud. Cutting-edge SupremeRAID™ GPU-based RAID removes the traditional RAID bottleneck to deliver maximum SSD performance without consuming CPU cycles or creating throughput bottlenecks, delivering unmatched flexibility, performance, and value. With headquarters in Silicon Valley supported by a robust R&D center in Taiwan, we are globally committed to spearheading advancements in storage solutions. For detailed product information, visit our website, or connect with us on Twitter (X) or LinkedIn.Contact InformationAndrea EakenDirector of Marketing, Americas & EMEA | Graid Technologyandrea.eaken@graidtech.com949-742-9928John C. MyungPresident, KLC Groupjohn@klc-group.com408-614-1414Related FilesSupremeRAID and CipherDriveOne Solution Brief_2024SOURCE: Graid Technology Inc. Copyright 2024 ACN Newswire via SeaPRwire.com.
More
Doubleview Provides Exploration Update at the Hat Polymetallic Mineral Deposit, 2024 Drilling Now Exceeds 7,500 m ACN Newswire

Doubleview Provides Exploration Update at the Hat Polymetallic Mineral Deposit, 2024 Drilling Now Exceeds 7,500 m

Vancouver, British Columbia--(Newsfile Corp. - October 1, 2024) - Doubleview (TSXV: DBG) (OTCQB: DBLVF) (FSE: 1D4) ("Doubleview" or the "Company") is pleased to announce that the 2024 drilling program at the Hat polymetallic mineral deposit, located in Northern British Columbia, has now surpassed 7,500 meters and is continuing. The company anticipates receiving the first assay results of the 2024 drilling season in the very near future. The drilling program will expand the mineral resource, infill areas with limited drill data, and extend the lateral and depth boundaries of the existing resource envelope, which remains open in all directions and at depth.The 2024 drill targets recognize the mineral resource block model from the recently completed Mineral Resource Estimate (MRE) and will increase the mineral resource and upgrade the confidence level of the resource categories. The drilling has met expectations, with visual results aligning with and confirming the block model's projections. The Hat deposit hosts several critical minerals as defined in the Canadian Critical Minerals Strategy, including copper, cobalt and, potentially, scandium, and possibly others.Farshad Shirvani, president & CEO of Doubleview, commented, "Year by year, the size of the Hat deposit has been increased by very targeted drilling, bringing it to a footprint of about 1.5km x 1.38km. Our technical and management team has excelled in this endeavor. Furthermore, we've discovered numerous additional elements within the Hat deposit that may become significant and enhance the resource: the Hat deposit may be unique among British Columbia's many. Recent moves by the governments of Canada and British Columbia in recognize the importance of critical minerals and announce targeted infrastructure investments in support of our industry and the many communities and businesses that directly benefit."Selected Drill Results Prior to 2024 Exploration:Every year Doubleview releases details of the year's drilling and activities. The Company website maintains all relevant information. Visual estimates indicate that 2024 drilling has exceeded expectations and will further validate the resource model and increase the dimensions of the mineral resource envelope. Table 1 provides previously announced key intersections, including copper equivalents and selected significant intercepts. These results, combined with the ongoing drilling program, are expected to further validate the Hat deposit's resource model and increase the dimensions of the Hat mineral resource envelope.Table 1: Selected drill results based on current commodity values applied in the resource estimate for the Hat deposit. For further details, refer to the full disclosure available on SEDAR+. https://www.newsfilecorp.com/release/225206Notes:- Metal equivalents should not be relied upon for future evaluations.- Drill hole intercepts included in this news release are core lengths that may or may not be true widths of mineralization. It is not possible to determine true widths.- Parameters used to calculate Copper Equivalent:Au price (US$/oz): 1900; Ag price (US$/oz): 24; Cu price (US$/lb): 4; Co price (US$/lb): 22.Au recovery: 89.0%; Ag recovery: 68.0%; Cu recovery: 84.0%; Co recovery: 78.0%.* Copper Equivalent CalculationCuEq in % = ([Ag grade in ppm] *24*0.68/31.1035 + [Au grade in ppm] *1900*.89/31.1035 + 0.0001* [Co grade in ppm] *22*0.78*22.0462 + 0.0001* [Cu grade in ppm] *4*0.84*22.0462)/(4*22.0462*0.84). Scandium is not part of the copper equivalent calculation.Core Samples Drill cores are processed at the Hat camp by an initial of examination by a senior geologist followed by detailed measurement and half-core sampling. One core half is retained at site for possible future re-examination and/or re-sampling for confirmation purposes, the other half is given a unique identification number, bagged and securely forwarded to an independent ISO-certified analytical laboratory for assaying. All standard QA/QC protocols are observed. Significant drill hole data and assay results will be released when received from the laboratory.Doubleview maintains a website at www.doubleview.ca. where previous assay results can be viewed.Qualified Persons:Erik Ostensoe, P. Geo., a consulting geologist, and Doubleview's Qualified Person with respect to the Hat Project as defined by National Instrument 43-101 Standards of Disclosure for Mineral Projects, has reviewed, and approved the technical contents of this news release. He is not independent of Doubleview as he is a shareholder in the company.About DoubleviewA mineral resource exploration and development company is headquartered in Vancouver, British Columbia, Canada. It is publicly traded on the TSX-Venture Exchange [TSX-V: DBG], [OTCQB: DBLVF], [GER: A1W038], and [Frankfurt: 1D4]. Doubleview focuses on identifying, acquiring, and financing precious and base metal exploration projects across North America, with a strong emphasis on British Columbia. The company enhances shareholder value through the acquisition and exploration of high-quality gold, copper, cobalt, scandium, and silver projects-collectively critical minerals-utilizing cutting-edge exploration techniques.Doubleview's success is deeply rooted in the unwavering support of its long-term shareholders, supporters, and institutional investors. Their ongoing commitment has been instrumental in advancing the company's strategic initiatives. Doubleview looks forward to further collaborative growth and development, and continues to welcome active participation from its valued stakeholders as the company expands its portfolio and strengthens its position in the critical minerals sector.About the Hat Polymetallic DepositThe Hat Deposit, located in northwestern British Columbia, is a polymetallic porphyry project with major resources of copper, gold, cobalt, and the potential for scandium. As one of the region's significant sources of critical minerals, the Hat deposit has undergone targeted exploration and development. The 0.2% CuEq cut-off resource estimate, as of the recently completed Mineral Resource Estimate and the Company's July 25, 2024 news release, is summarized below: Average GradeMetal ContentOpen Pit Model HatResource CategoryTonnageCuEqCuCoAuAgCuEqCuCoAuAgMt%%%g/tg/tmillion lbmillion lbmillion lbthousand ozthousand ozIn PitIndicated1500.4080.2210.0080.190.421,353733289292,045Inferred4770.3440.1850.0090.150.493,6191,945912,3287,575 Scandium potential for the Hat Deposit is estimated to be 300 to 500 million tonnes at an average grade of 40 ppm (0.004%) Sc2O3.For further details, please refer to the Company's July 25, 2024 news release.On behalf of the Board of Directors,Farshad Shirvani, President & Chief Executive OfficerFor further information please contact:DoubleviewVancouver, BC Farshad ShirvaniPresident & CEOInstitutional Investor Line: (604) 607-5470T: (604) 678-9587E: corporate@doubleview.caNEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.Certain of the statements made and information contained herein may constitute "forward-looking information." In particular references to the Mineral Resource Estimate and future work programs or expectations on the quality or results of such work programs are subject to risks associated with operations on the property, exploration activity generally, equipment limitations and availability, as well as other risks that we may not be currently aware of. Accordingly, readers are advised not to place undue reliance on forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information, whether as a result of new information, future events or otherwise.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/225206 Copyright 2024 ACN Newswire via SeaPRwire.com.
More
ICMS Introduces New IT Degree Programs to Address Growing Industry Demand SeaPRwire

ICMS Introduces New IT Degree Programs to Address Growing Industry Demand

Sydney, Australia – October 02, 2024 – (SeaPRwire) – In response to the growing demand for skilled IT professionals, the International College of Management, Sydney (ICMS) has introduced new cutting-edge degree programs in Information Technology. The ICMS Bachelor of Information Technology program offers specialised pathways in both Cybersecurity and Big Data and Analytics, catering to the increasing demand for skilled IT experts in today’s technology-driven world. Through a blend of theoretical knowledge and practical experience gained through the ICMS Work Integrated Learning Program, students are not only equipped to enter the IT industry but also thrive in diverse career opportunities within fields like ICT Business Analysis, Database Administration, Systems Analysis, Business Intelligence Analysis, and IT Support. With the IT industry in Australia projected to show significant growth, the Bachelor of Information Technology degree serves as a gateway to a rewarding career path filled with innovation and professional success. Internships as part of the IT degree a key differentiator To enhance the educational experience, ICMS has integrated industry placements into its curriculum. By partnering with over 1,000 industry leaders, students gain invaluable practical experience alongside their academic studies, ensuring they are well-prepared for the demands of the real world. “Our collaborations are essential in offering students genuine exposure to industry practices, a fundamental aspect of our educational approach,” President and Managing Director of ICMS, Rowan Courtney-O’Connor, said. Global student community In alignment with the 3.5% surge in higher education enrollments in Australia for 2024, particularly driven by international students, ICMS has broadened its learning pathways to include online and hybrid courses, subject to availablity. This adaptive approach caters to a diverse range of student needs, reflecting ICMS’s commitment to accessibility and inclusivity. Committed to student success, ICMS provides a range of support services such as career counseling and mentorship, facilitating a seamless transition from academia to professional settings. With a vibrant student community representing over 55 countries, ICMS integrates global perspectives into its curriculum, enriching the learning experience for all. About ICMS The International College of Management, Sydney (ICMS) is a prestigious higher education institution with campuses in Manly and Sydney’s business district. Founded in 1996, ICMS is a leader in career-focused, quality education and offers bachelor’s and master’s degrees to Australian and international students. Aligned with the Australian Qualifications Framework (AQF), ICMS degrees hold international recognition among various industry partners. Embracing an applied learning approach, ICMS focuses on delivering a dynamic student experience that aligns closely with current workplace demands. Backed by a faculty of seasoned professionals with rich industry backgrounds and a dedication to teaching excellence, ICMS offers courses that flexibly cater to individual strengths and interests. The institution’s Work Integrated Learning (WIL) program, supported by a vast network of industry leaders, integrates work placements into all levels of study, enriching students with invaluable practical insights and paving the way for their success. ICMS extends its support to both domestic and international students through scholarship opportunities and provides a picturesque learning environment at its Northern Beaches Campus overlooking Manly Beach, complemented by the vibrant City Campus in Sydney. This unique blend of academic rigour, industry partnerships, and scenic campuses sets ICMS apart, offering students a holistic and personalised educational journey. Contact Information Brand: International College of Management, Sydney (ICMS) Contact: Stephen Dally, Vice President (Marketing) Email: sdally@icms.edu.au Website: https://www.icms.edu.au The article is provided by a third-party content provider. SeaPRwire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Sectors: Top Story, Corporate News SeaPRwire provides real time press release distribution for companies and organizations to 6,500+ media outlets & 3.5 million professional desktops in 90 regions. It distributes press releases in different languages, including: IndonesiaFolk, IndoNewswire, SEATribune, IDNewsZone, LiveBerita, DailyBerita, TaiwanPR, SinchewBusiness, AsiaEase, BuzzHongKong, SingapuraNow, TIHongKong, TaipeiCool, TWZip, AsiaFeatured, dePresseNow, THNewson, KULPR, VNFeatured, MENAEntry, HunaTimes, DubaiLite, ArabicDir, BeritaDaring, TekanAsia, JamKopi ...
More

Fungushead Launches New Cordyceps Mushroom Liquid Culture

A Meeting Point between Nature and Modern Science for the Naturally Inclined; a Breakthrough in Holistic Health. Santa Cruz, CA – October 02, 2024 – (SeaPRwire) – Fungushead, the premier online destination for all things mushroom-based, today unveils its newest offering: Cordyceps Liquid Culture. Cordyceps mushrooms are prized in traditional Chinese medicine (TCM), and Fungushead has thankfully made the world-famous Cordyceps militaris available to the people. This product represents a new item in Fungushead’s line of mushroom strains, each expressing the company’s dedication to holistic health and alternative medicines. Compared to other fungi in stock, Cordyceps has countless benefits that resonate with Fungushead’s clientele. As adaptogens, the Cordyceps mushroom may help the body react properly to stress. It is also known to aid with energy, endurance, immunity and overall health! Priced at $25, the Cordyceps Liquid Culture comes in a user-friendly format straight from the bottle, including a 10mL syringe for accurate application. The liquid culture has multiple use cases, from scientific to educational purposes to cultivation. Fungushead products offer beginners and seasoned mycophiles a way to satisfy their curiosity and learn more about the incredible world of fungi. This is only possible if they procure mushroom strains with good genetics, which Fungushead delivers in spades. Jackson Dean, CEO said, “Any mushroom grower worth their salt knows that the most important part of the harvest is good genetics. This is why we are here, to bring some of the best genetics the market has seen and makes the grower’s life easier. Our syringes also come with a researcher guarantee, too, which means we’ll send you another one for free if anything goes wrong. Learn more about our Cordyceps Liquid Culture by checking out https://fungusheadshop.com/product/cordyceps-liquid-culture/. You can also visit https://fungusheadshop.com/ to find other liquid cultures, as well as sponge syringe, prints, swabs, and new strains. Finally, fill out our contact form at https://fungusheadshop.com/contact-us/ for questions and inquiries. Social Links Facebook: https://www.facebook.com/fungusheads/ X: https://x.com/Fungusheads YouTube: https://www.youtube.com/@Fungusheads Instagram: https://www.instagram.com/fungusheads/ Media Contact Brand: Fungushead Contact: Media team Email: support@fungusheadshop.com Website: https://fungusheadshop.com The article is provided by a third-party content provider. SeaPRwire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Sectors: Top Story, Corporate News SeaPRwire provides real time press release distribution for companies and organizations to 6,500+ media outlets & 3.5 million professional desktops in 90 regions. It distributes press releases in different languages, including: IndonesiaFolk, IndoNewswire, SEATribune, IDNewsZone, LiveBerita, DailyBerita, TaiwanPR, SinchewBusiness, AsiaEase, BuzzHongKong, SingapuraNow, TIHongKong, TaipeiCool, TWZip, AsiaFeatured, dePresseNow, THNewson, KULPR, VNFeatured, MENAEntry, HunaTimes, DubaiLite, ArabicDir, BeritaDaring, TekanAsia, JamKopi ...
More
PocketHealth 推出新的乳腺健康工具,帮助尽早发现乳腺癌 Finance

PocketHealth 推出新的乳腺健康工具,帮助尽早发现乳腺癌

乳腺癌仍然是加拿大女性中最常见的癌症,但早期发现可以挽救生命。PocketHealth 正在推出新的乳腺健康工具,旨在让人们更容易积极管理自己的乳腺健康并尽早发现癌症。 随着安大略省乳腺筛查计划 (OBSP) 本月下旬将筛查资格扩大到 40 岁的年轻人,PocketHealth 的工具通过个性化的风险评估、筛查资格通知和后续护理建议来促进早期发现。这些工具使个人能够评估其乳腺癌风险,根据区域指南管理乳腺X光检查资格,并更好地了解其筛查结果。 PocketHealth 的乳腺健康工具首先在安大略省推出,简化了乳腺X光检查报告中复杂的医学术语,检测和展示后续影像建议,并为患者提供与医生交谈的个性化问题。 随着筛查资格的扩大,这些工具对于 40-49 岁的可能从未定期接受乳腺X光检查的人来说尤其重要。 (SeaPRwire) - 多伦多, 2024 年 10 月 1 日 – 今天宣布在其平台内推出新的 工具,旨在帮助患者更有效地管理他们的乳腺健康旅程。这些工具使个人能够进行个性化的乳腺癌风险评估和简化的乳腺X光检查管理,旨在提高乳腺癌的早期发现率,并让患者更好地控制自己的乳腺健康。 尽管乳腺癌是女性中最常见的癌症,占 ,但过去十年中超过 的人没有及时进行乳腺X光检查。 虽然各个省或地区对筛查建议和获取途径各有不同,但早期发现仍然至关重要,早期发现乳腺癌时 。为了解决筛查获取和参与方面的差距,PocketHealth 的新的乳腺健康工具旨在为个人提供必要的支持,帮助他们管理筛查,更好地了解其个人风险,并在其乳腺健康旅程中采取积极措施。 主要功能包括: 个性化的风险评估:免费计算个性化的乳腺癌风险评分,使用行业标准化模型提供 5 年和终身风险估计。 筛查资格提醒:向安大略省 40-49 岁的符合条件的患者发送早期乳腺X光检查筛查通知,并提供预订乳腺X光检查的支持。 更好地理解乳腺健康:定义乳腺X光检查报告中复杂的医学术语,突出后续建议,使患者能够更好地了解其乳腺影像结果。 通过个性化的乳腺健康见解实现更多控制:在整个影像旅程中提供全面的支持,为患者提供在下次预约时询问医生 的个性化问题,以及推荐后续检查的通知,例如进一步的影像检查或活检。 “PocketHealth 的乳腺健康工具在个人如何积极管理其乳腺健康方面取得了重大进展,”PocketHealth 的集团产品经理 Kaelynd Gouveia 表示。“从个性化的风险评估到整个筛查过程中的支持,我们正在为人们提供他们需要的工具,让他们掌控自己的健康,并带着自信做出决定,因为他们知道自己在合适的时间获得了正确的信息。” 随着安大略省乳腺筛查计划 (OBSP) 从2024 年 10 月开始将资格扩大到包括 40 岁的年轻人,PocketHealth 的工具提供及时、个性化的指导。这些工具确保个人迅速采取行动,及时了解关键筛查,并积极管理他们的乳腺健康,从而降低错过早期发现机会的风险。 “当我被诊断出患有乳腺癌时,PocketHealth 在那个感觉完全不可控的时间给了我一种掌控感。我能够根据自己的意愿查看我的报告并准备好我的问题,”乳腺癌幸存者 Patti A. 说。“能够即时获取重要的医疗信息,尤其是在乳腺癌筛查期间,至关重要。早期发现可以挽救生命,能够通过实时访问您的记录来掌控您的健康旅程,这既能带来安心,又能赋予力量。” 这些新工具将在安大略省向符合条件的患者提供,之后将在北美的其他地区推广。 关于 PocketHealth PocketHealth 是唯一的以患者为中心的图像共享平台,使患者能够轻松访问和参与他们的诊断影像记录。通过消除任何网络图像共享依赖关系,PocketHealth 无缝集成到医疗保健系统,为提供者创造效率和成本节约,同时让患者掌控自己的医疗保健旅程。PocketHealth 受到北美超过 800 家医院和影像中心的信赖,并被超过 150 万患者使用。请访问 了解更多信息。 SOURCE PocketHealth本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More
修复 Pokemon Go 无法检测位置错误 12 – 无需封禁和越狱 Finance

修复 Pokemon Go 无法检测位置错误 12 – 无需封禁和越狱

(SeaPRwire) - 纽约, 2024年9月30日 — 最近,许多 Pokémon Go 玩家在使用位置更改应用程序时遇到了“无法检测到位置 12”的错误。有些人转向非官方的第三方破解工具来修复它,但这些工具不可靠,会使账户面临风险。“然而, 已经取得突破,彻底解决了‘Pokémon Go 错误 12’。它允许您修改 Pokémon Go 的位置,无需破解应用程序或越狱,”Tenorshare 发言人表示。 为什么 Pokémon Go 会显示无法检测到位置 12 错误? 通常,Pokémon Go 中的“无法检测到位置 12”错误发生在使用不可靠的位置更改应用程序时。这些应用程序可能无法正确掩盖您的 GPS 位置,或者会干扰游戏的定位服务,从而导致此问题。许多用户不得不求助于第三方工具,这些工具要求他们使用游戏破解版作为“Pokémon Go 错误 12”的修复方法。 然而, 是市场上首款提供无需破解或越狱的解决方案的软件。凭借其先进的技术,它可以解决 iPhone 或其他设备上的“Pokémon Go 无法检测到位置 12”问题,而不会影响您的游戏账户安全性。 [9 月更新] 无需修改应用程序即可修复 Pokémon Go 错误 12(安全稳定) 您可以使用 Tenorshare iAnyGo 在不修改应用程序的情况下修复“Pokémon Go 错误 12”,这意味着它不需要游戏的破解版。iAnyGo 可以帮助您正确欺骗您的位置,以便您可以从世界任何地方玩 Pokémon Go,而无需离开您家舒适的环境。以下是此工具的主要功能: 修复 iOS/Android 设备上的“Pokémon Go 无法检测到位置 12”错误。 以选定速度自动移动。 冷却计时器以防止封禁。 导入 GPX 文件以规划自定义路线。 放大以改善规划。 模拟步行、骑自行车或驾驶速度。 保存您的收藏位置,以便快速访问。 在需要时停止移动。 使用 GPS 操纵杆进行轻松控制。 遵循包含两个或更多点的路线。 支持 iOS 18 和 Android 15。 一次最多可在 15 台设备上更改位置。 请按照以下步骤使用 iAnyGo 修复 Pokémon Go 上的错误 12: 步骤 1:在您的计算机上打开 iAnyGo。然后,选择“更改位置”。步骤 2:将您的 iPhone/Android 连接到同一台 PC 并开始在给定地图上欺骗位置。 视频指南: Tenorshare 在 iOS 18 和 iPhone 16 上推出大优惠! 为了庆祝 iOS 18,Tenorshare 正在举行 。参加活动的使用者将有机会获得 iPhone 16 和 Tenorshare 产品的折扣,这些产品将改善他们的 iOS 18 体验。 关于 Tenorshare Tenorshare iAnyGo 帮助修复“Pokémon Go 无法检测到位置 12”错误,无需修改原始 Pokémon Go 应用程序,并允许您安全地欺骗您的位置。智能手机解决方案提供商 Tenorshare 始终在寻找新的 iOS/Android 错误的解决方案。 更多信息: 此新闻稿是通过 Send2Press® 代表新闻来源发布的。有关更多信息,请访问 Send2Press Newswire 网站: . 来源 Tenorshare Co. Ltd.本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More
Els 报告飓风海伦的影响微乎其微 Finance

Els 报告飓风海伦的影响微乎其微

(SeaPRwire) - 芝加哥, 2024 年 9 月 30 日 — Equity LifeStyle Properties, Inc. (纽约证券交易所代码:ELS)(本文称“公司”、“我们”、“我方”和“我们的”)今日报告了其对飓风海伦对位于佛罗里达州、北卡罗来纳州和南卡罗来纳州的房产的影响的初步评估。 据报道,我们的居民、宾客或员工均未受伤。某些房产受到洪水、风、风吹来的碎片以及树木和树枝倒塌的影响。我们正在估算与清理和修复工作相关的成本。我们相信我们拥有足够的保险,包括商业中断保险,但需支付免赔额。目前,我们认为飓风海伦不会对我们的经营成果或合并报表中的财务状况产生重大影响。 本新闻稿包含《1995 年私人证券诉讼改革法案》含义内的某些“前瞻性陈述”。当使用诸如“预期”、“预计”、“相信”、“预测”、“估计”、“指导”、“打算”、“可能是”和“将是”等词语或短语,或者其否定形式时,除非上下文要求,否则旨在识别前瞻性陈述,并且可能包括但不限于有关我们对未来的预期、目标或意图以及我们收购的预期影响的信息。前瞻性陈述,其本质上涉及估计、预测、目标、预测和假设,并且受到风险和不确定性的影响,这些风险和不确定性可能导致实际结果或后果与前瞻性陈述中表达的内容存在重大差异,原因是许多因素,包括但不限于以下因素:(i)投资组合内场地使用情况的组合;(ii) 我们短期度假村和码头场地的收益管理;(iii) 社区、度假村和码头场地的计划或已实施的费率上涨;(iv) 会员资格订阅年度付款的计划或已实施的费率上涨;(v) 占用率变化;(vi) 我们吸引和留住会员客户的能力;(vii) 针对旅行和户外度假目的地的客户需求变化;(viii) 我们在通货膨胀环境下管理费用的能力;(ix) 债务偿还和利率的变化; (x) 我们按照我们的估计整合和运营最近收购的能力;(xi) 我们在影响供应链或劳动力市场的变化面前执行扩张/开发机会的能力;(xii) 正在进行的交易的全部完成以及在假定的时间表上完成;(xiii) 我们吸引和留住房产员工的能力,尤其是季节性员工;(xiv) 正在进行的法律事项和相关费用;(xv) 在风暴或其他意外事件后恢复房产运营的成本以及潜在的收入损失;以及 (xvi) 对我们内部控制的重大弱点的影响以及我们纠正这些弱点的能力财务报告。 有关可能影响我们以及本文所述陈述的其他因素的更多信息,请参阅我们提交给美国证券交易委员会的文件,包括我们最近的 10-K 表格年度报告以及任何后续的 10-Q 表格季度报告中的“风险因素”和“前瞻性陈述”部分。 这些前瞻性陈述基于管理层对未来事件的当前预期和信念。与任何预测或预测一样,这些陈述本质上容易受到不确定性和情况变化的影响。我们没有义务,并且明确拒绝任何义务,无论由于此类变化、新信息、后续事件或其他原因,更新或更改我们的前瞻性陈述。 我们是一家完全整合的以生活方式为导向的房产所有者,截至2024 年 7 月 22 日,拥有或拥有位于美国的 452 处房产的权益,其中主要位于美国,共计 172,866 个场地。我们是一家总部位于芝加哥的自营自管房地产投资信托基金。 来源 Equity LifeStyle Properties, Inc.本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More
TIME for Kids 继续开展“服务之星”计划 并宣布新的“月度之星”:10 岁的反饥饿倡导者 Elaina Johnson Latest News

TIME for Kids 继续开展“服务之星”计划 并宣布新的“月度之星”:10 岁的反饥饿倡导者 Elaina Johnson

(SeaPRwire) - 由Allstate基金会支持,Service Stars表彰为社会做出积极贡献的年轻人 今天,TIME for Kids继续开展其Service Stars项目,并宣布了2024-2025学年首位“月度之星”:来自科罗拉多州布鲁姆菲尔德的10岁女孩Elaina Johnson,她因致力于对抗社区中的粮食不安全问题而受到认可。 探索她的故事。 TIME for Kids Service Stars项目由**The Allstate Foundation**提供资金支持。 TIME for Kids Service Stars现已进入第二年,该项目专为8至14岁的年轻人设计,他们渴望让世界变得更美好。该项目为孩子们(以及家庭、教育工作者和社区团体)提供了所需的资源和灵感,以推动他们所在社区的积极变化。每月,一个主题任务鼓励孩子们采取行动——例如传播善意、筹款或保护地球——并选出一位杰出的孩子,并在TIME for Kids的封面故事中作为“月度之星”展示。 “我们很高兴进入我们成功的Service Stars项目的第二年,分享更多关于在社区中做出善行和服务的孩子们的感人故事,”TIME for Kids主编安德烈娅·德尔班科说。“我们的目标是激励读者,并为他们提供他们需要采取行动的信息——任何服务行为都不容小觑。” “Allstate基金会很荣幸能与TIME for Kids合作开展Service Stars项目,”Allstate基金会青年赋权项目主管格雷格·韦瑟福德二世说。“我们相信年轻人有能力在社区中做出重大贡献。通过表彰这些非凡的孩子并提供这些Service Stars资源,我们希望激励年轻人采取行动,为所有人创造一个更美好的未来。” 提名一位Service Star,并获取免费文章和资源。 ###本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More